TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17539894

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d. with naltrexone 50 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Naltrexone 50 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d. and Tegaserod with naltrexone 50 mg
Number of subjects: 48
Study: 15882796

Group type: EXPERIMENTAL
Intervention: Self-paced trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple reaction time instruction
Number of subjects: 0
Study: 11426365

Group type: EXPERIMENTAL
Intervention: Vital Capacity Maneuver (VCM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no VCM)
Number of subjects: 40
Study: 9412612

Group type: EXPERIMENTAL
Intervention: Piracetam (12 g as an initial intravenous bolus, 12 g daily for 4 weeks, and 4.8 g daily for 8 weeks)
Number of subjects: 927

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: Piracetam (in early treatment subgroup)
Number of subjects: 927

Group type: COMPARATOR
Intervention: Placebo (in early treatment subgroup)
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: Piracetam (in subgroup of patients with moderate and severe stroke)
Number of subjects: 927
Study: 8213795

Group type: EXPERIMENTAL
Intervention: Epoetin alfa solution
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Vehicle (including citrate component)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Citrate component of the vehicle
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Albumin component of the vehicle
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 36
Study: 3688536

Group type: EXPERIMENTAL
Intervention: 60% nitrous oxide
Number of subjects: 18

Group type: COMPARATOR
Intervention: 60% nitrogen (control)
Number of subjects: 18
Study: 30967131

Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention (HBEI) for 12 weeks, including four 2-hour sessions supervised by a physiotherapist and fortnightly telephone support, combined with health education.
Number of subjects: 171

Group type: COMPARATOR
Intervention: Health education only (Control group).
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention (HBEI) for 12 weeks.
Number of subjects: 171
Study: 29109237

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sleep Control
Number of subjects: 0
Study: 25439595

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 759

Group type: COMPARATOR
Intervention: sham/0.5 mg crossover
Number of subjects: 759

Group type: COMPARATOR
Intervention: sham/0.5 mg
Number of subjects: 759
Study: 24132734

Group type: EXPERIMENTAL
Intervention: Older age at diagnosis
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Larger left ventricular (LV) end-diastolic M-mode dimension z-score
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Lower septal peak systolic tissue Doppler velocity z-score
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Classification and regression tree analysis
Number of subjects: 127
Study: 21705283

Group type: EXPERIMENTAL
Intervention: Nike Sensory Station assessments
Number of subjects: 161
Study: 19156027

Group type: EXPERIMENTAL
Intervention: Perftoran
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 50
Study: 16537288

Group type: EXPERIMENTAL
Intervention: Physician characteristics (community vs academic affiliation, enthusiastic vs neutral presentation, new vs previous relationship)
Number of subjects: 262
Study: 12743672

Group type: EXPERIMENTAL
Intervention: Ximelagatran 20 mg twice daily, administered either before breakfast and with dinner, or with breakfast and after dinner.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single oral doses of ximelagatran (1-98 mg) in a dose-escalation study.
Number of subjects: 0
Study: 11074230

Group type: EXPERIMENTAL
Intervention: Late partial sleep deprivation (sleep 9:00 PM‐1:00 AM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Early partial sleep deprivation (sleep 3:00 AM‐7:00 AM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Midfollicular (MF) phase
Number of subjects: 30

Group type: COMPARATOR
Intervention: Late luteal (LL) phase
Number of subjects: 30
Study: 9058867

Group type: EXPERIMENTAL
Intervention: Reversed polarity (distal electrode = anode)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Initial polarity (distal electrode = cathode)
Number of subjects: 27
Study: 8362451

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mebendazole (400 mg)
Number of subjects: 0
Study: 30357555

Group type: EXPERIMENTAL
Intervention: SCC plus systematic EPC
Number of subjects: 186

Group type: COMPARATOR
Intervention: SCC plus on-demand EPC
Number of subjects: 186
Study: 30070733

Group type: EXPERIMENTAL
Intervention: 5% CSPS dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5% CSPS slurry
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0% CSPS dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5% CSPS dentifrice and 0% CSPS dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study: 27614872

Group type: EXPERIMENTAL
Intervention: GC + N (Gemcitabine, Cisplatin + Necitumumab)
Number of subjects: 96

Group type: COMPARATOR
Intervention: GC (Gemcitabine, Cisplatin)
Number of subjects: 96
Study: 24495781

Group type: EXPERIMENTAL
Intervention: 6‐month extended contact intervention (Get Healthy, Stay Healthy, GHSH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No contact control group (standard practice following GHS completion)
Number of subjects: 0
Study: 22214924

Group type: EXPERIMENTAL
Intervention: Unstimulated salivary cortisol
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Salivary cortisol at 2300 h
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Dexamethasone-suppressed salivary cortisol at 0800 h
Number of subjects: 262
Study: 20462038

Group type: EXPERIMENTAL
Intervention: Kangliu Zengxiao Decoction (KLZX) in addition to chemotherapy NP regimen
Number of subjects: 61

Group type: COMPARATOR
Intervention: Chemotherapy NP regimen alone
Number of subjects: 61
Study: 18678792

Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion hydrochloride started at 150 mg/d and increased to 400 mg/d
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride started at 50 mg/d and increased to 200 mg/d
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Extended-release venlafaxine hydrochloride started at 37.5 mg/d and increased to 375 mg/d
Number of subjects: 727
Study: 15900007

Group type: EXPERIMENTAL
Intervention: Doxorubicin (50 mg/m2) plus docetaxel (75 mg/m2)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Doxorubicin (60 mg/m2) plus cyclophosphamide (600 mg/m2)
Number of subjects: 627
Study: 12727169

Group type: EXPERIMENTAL
Intervention: Modified small bowel follow-through (SBFT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional management (Control group)
Number of subjects: 62
Study: 10321329

Group type: EXPERIMENTAL
Intervention: R3 component of the blink reflex in MS patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 20
Study: 8712652

Group type: EXPERIMENTAL
Intervention: 30 mg morphine sulphate (MST) and 10 mg metoclopramide every 8 h for 48 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: 75 mg diclofenac twice daily for 48 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 mg morphine sulphate (MST)
Number of subjects: 0
Study: 1655107

Group type: EXPERIMENTAL
Intervention: Sorbinil (250 mg day‐1) for 4 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sorbinil (250 mg day‐1) for 52 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Open label Sorbinil for 52 weeks
Number of subjects: 23
Study: 7035745

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy including platinum
Number of subjects: 250

Group type: COMPARATOR
Intervention: Single agent chemotherapy
Number of subjects: 250
Study: 29989335

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla300)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Insulin degludec U100 (Deg)
Number of subjects: 24
Study: 27935229

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 27805473

Group type: EXPERIMENTAL
Intervention: Link with no disclosure
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Link with a simple nonsponsorship disclosure
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Link with a detailed nonsponsorship disclosure
Number of subjects: 1071

Group type: COMPARATOR
Intervention: Control (no link to a disease information website)
Number of subjects: 1071
Study: 25030181

Group type: EXPERIMENTAL
Intervention: Exenatide 2.5 µg + insulin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Insulin alone (control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pramlintide 30 µg + insulin
Number of subjects: 10
Study: 21257052

Group type: EXPERIMENTAL
Intervention: Low-concentrate diet plus enzyme (LCE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-concentrate diet (HC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-concentrate diet (LC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-concentrate diet plus enzyme (HCE)
Number of subjects: 60
Study: 19497153

Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 39

Group type: COMPARATOR
Intervention: OC1/20
Number of subjects: 39
Study: 17702884

Group type: EXPERIMENTAL
Intervention: Personalized, nonpharmacological interventions
Number of subjects: 167
Study: 14741079

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg/day for 6 days
Number of subjects: 130

Group type: COMPARATOR
Intervention: Nimesulide 200 mg/day
Number of subjects: 130
Study: 11515737

Group type: EXPERIMENTAL
Intervention: Loss-framed, multicultural messages
Number of subjects: 752

Group type: COMPARATOR
Intervention: Gain-framed, multicultural messages
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Loss-framed, ethnic-targeted messages
Number of subjects: 752
Study: 9777717

Group type: COMPARATOR
Intervention: Erig PMC (40 IU kg(‐1) via intramuscular route)
Number of subjects: 98

Group type: COMPARATOR
Intervention: PHT‐Erig (40 IU kg(‐1) via intramuscular route)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Erig PMC (40 IU kg(‐1) via intramuscular route) with PVRV
Number of subjects: 98

Group type: COMPARATOR
Intervention: PHT‐Erig (40 IU kg(‐1) via intramuscular route) with PVRV
Number of subjects: 98
Study: 7906108

Group type: EXPERIMENTAL
Intervention: Atropine, 5 micrograms/kg (Group 1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate, 2.5 micrograms/kg (Group 2)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Transesophageal atrial pacing (Group 3)
Number of subjects: 64
Study: 2460568

Group type: EXPERIMENTAL
Intervention: Topical interferon gel (10^6 IU of leukocyte interferon/g)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Topical interferon gel with nonoxynol-9
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (gel base alone)
Number of subjects: 89
Study: 31595423

Group type: EXPERIMENTAL
Intervention: CoQ10 (300 mg, once daily) for 12 months in RTT patients
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CoQ10 (300 mg) for 30 days in healthy adults
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: EGCG (1 g green tea extract containing 50% EGCG) for 30 days in healthy adults
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 U.I.) for 30 days in healthy adults
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g) for 30 days in healthy adults
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Resveratrol (325 mg) for 30 days in healthy adults
Number of subjects: 26
Study: 29864295

Group type: EXPERIMENTAL
Intervention: Drifting bi-Maxwellians modeling of ion components
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Long-wavelength instabilities
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Resolved proton beam presence
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Unstable spectra
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Unstable spectra with large He^{2+} drift speeds
Number of subjects: 309
Study: 28117133

Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 139

Group type: COMPARATOR
Intervention: CYP2C19 genetic polymorphisms
Number of subjects: 139
Study: 26169093

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 80
Study: 23688751

Group type: EXPERIMENTAL
Intervention: Low-dose rituximab combined with glucocorticoids (prednisone 60, 30, 20, 10 mg/day on days 5-28)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Low-dose rituximab combined with glucocorticoids (prednisone)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (dexamethasone 40 mg/day on days 1-4, followed by rituximab 100 mg on days 7, 14, 21, 28)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 74
Study: 21492145

Group type: EXPERIMENTAL
Intervention: Happy participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sad participants
Number of subjects: 0
Study: 18725240

Group type: EXPERIMENTAL
Intervention: Positive group (n=9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Negative group (n=8)
Number of subjects: 17
Study: 17315708

Group type: EXPERIMENTAL
Intervention: Standard therapy plus 10 longidase injections in a dose of 3000 IU
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 28
Study: 12817526

Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg alone for 10 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Digoxin 0.25 mg with Crataegus special extract WS 1442 (hawthorn) 450 mg twice daily for 21 days
Number of subjects: 8
Study: 10917408

Group type: EXPERIMENTAL
Intervention: Gabapentin (600 to 3,600 mg/day)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 8672615

Group type: EXPERIMENTAL
Intervention: Metamizol (1 g/100 ml NaCl 0.9%)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo (100 ml NaCl 0.9%)
Number of subjects: 117
Study: 1479527

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 6375890

Group type: EXPERIMENTAL
Intervention: Injections of tyrosine-adsorbed, glutaraldehyde-modified Dermatophagoides pteronyssinus antigen
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Active treatment and placebo
Number of subjects: 51
Study: 31298494

Group type: EXPERIMENTAL
Intervention: Sacral massage for 30 minutes during labor
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 30100320

Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Remote Myofascial Release (MFR)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Combination of SS and remote MFR
Number of subjects: 58

Group type: COMPARATOR
Intervention: Self‐administered interventions (all groups)
Number of subjects: 58
Study: 27051992

Group type: EXPERIMENTAL
Intervention: Caffeinated drink (80 mg of caffeine)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Decaffeinated drink
Number of subjects: 104
Study: 25725933

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral THC 10-mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral THC 20-mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral THC (10-mg and/or 20-mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral THC
Number of subjects: 14
Study: 23593607

Group type: EXPERIMENTAL
Intervention: ETV (1 mg) monotherapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: LAM+ADV combination therapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ETV (1 mg)+ADV combination therapy
Number of subjects: 48
Study: 20131569

Group type: EXPERIMENTAL
Intervention: Reacher
Number of subjects: 41

Group type: COMPARATOR
Intervention: Unaided hand
Number of subjects: 41
Study: 18389339

Group type: EXPERIMENTAL
Intervention: Benidipine administered orally for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benidipine in vitro
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benidipine with L-arginine
Number of subjects: 0
Study: 16669729

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 572

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 572
Study: 12786707

Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis (2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 11129741

Group type: EXPERIMENTAL
Intervention: Hospital-based general exercise program
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 300
Study: 9175387

Group type: EXPERIMENTAL
Intervention: Intracervical misoprostol (100 ug)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravaginal misoprostol (100 ug)
Number of subjects: 100
Study: 8181831

Group type: EXPERIMENTAL
Intervention: Porous hydroxyapatite in blocks (HA-B)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Porous hydroxyapatite in granules (HA-G)
Number of subjects: 2
Study: 3083212

Group type: EXPERIMENTAL
Intervention: Sorbinil (250 mg qd)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Sorbinil (for 3 weeks)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (in single-blind fashion)
Number of subjects: 47
Study: 29572130

Group type: EXPERIMENTAL
Intervention: Telephone-delivered exercise therapy by physiotherapists
Number of subjects: 20
Study: 26865258

Group type: EXPERIMENTAL
Intervention: BWL+H
Number of subjects: 201

Group type: COMPARATOR
Intervention: BWL
Number of subjects: 201
Study: 24894077

Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy (HT) performed by a qualified therapist, 6 sessions over 3 months
Number of subjects: 260

Group type: COMPARATOR
Intervention: Gut-directed hypnotherapy (HT) through self-exercises at home using CD, 3 months
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Both therapies (individual HT and CD-based HT)
Number of subjects: 260
Study: 23914827

Group type: EXPERIMENTAL
Intervention: Standard medical care plus pelvic physiotherapy (maximum of six contacts)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard medical care (at least three contacts during five months)
Number of subjects: 0
Study: 20178872

Group type: EXPERIMENTAL
Intervention: Balneotherapy (BT)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 237
Study: 18231889

Group type: EXPERIMENTAL
Intervention: Standard treatment plus acupuncture (n=125)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Standard treatment plus specific stabilising exercises (n=131)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Standard treatment alone (n=130)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 386
Study: 16680474

Group type: EXPERIMENTAL
Intervention: Organ-preserving pancreatic head resection (OPPHR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pylorus-preserving pancreaticoduodenectomy (PPPD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both OPPHR and PPPD
Number of subjects: 40
Study: 12490815

Group type: EXPERIMENTAL
Intervention: High-energy transurethral microwave thermotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral microwave thermotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate
Number of subjects: 0
Study: 10885549

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open cholecystectomy (conventional laparotomy)
Number of subjects: 0
Study: 8831438

Group type: EXPERIMENTAL
Intervention: Lithium doses adjusted to achieve a serum lithium concentration of 0.8 to 1.0 mmol/liter (standard)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lithium doses adjusted to achieve a serum lithium concentration of 0.4 to 0.6 mmol/liter (low)
Number of subjects: 90
Study: 1426392

Group type: EXPERIMENTAL
Intervention: Subconjunctival antibiotics and steroids
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical antibiotics and steroids
Number of subjects: 60
Study: 3897156

Group type: EXPERIMENTAL
Intervention: Mixed-beam treatment (neutron/photon)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Photon radiation therapy (X ray)
Number of subjects: 91
Study: 31888569

Group type: EXPERIMENTAL
Intervention: FANMI intervention (community-based cohort care)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard care (routine HIV care and individual counseling)
Number of subjects: 160
Study: 29770998

Group type: EXPERIMENTAL
Intervention: High maternal depressive symptoms (MDS)
Number of subjects: 2934

Group type: COMPARATOR
Intervention: Low maternal depressive symptoms (MDS)
Number of subjects: 2934
Study: 27392137

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 12

Group type: COMPARATOR
Intervention: Donepezil and Placebo
Number of subjects: 12
Study: 23361084

Group type: EXPERIMENTAL
Intervention: secukinumab (10 mg/kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study: 22584134

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (systolic BP <120 mmHg)
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Standard blood pressure control (systolic BP 130‐139 mmHg)
Number of subjects: 1028
Study: 20333742

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Local narrow-band ultraviolet B (NB-UVB)
Number of subjects: 19